Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | FES | P07332 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595604 | 0.86 | CDK8 (0.49) | KCNH2SCN5ASCN9AKDRSYK | |
| SCHEMBL3589681 | 0.83 | SYK (0.48) | CDK2SYKMAPTLMNAMEN1 | |
| SCHEMBL3583812 | 0.83 | SYK (0.61) | KDRAURKACLK4CDK1CDK2 | |
| SCHEMBL3600524 | 0.83 | APP (0.62) | AURKASYKMAPK8AURKB | |
| SCHEMBL24867205 | 0.83 | SCN9A (0.54) | KCNH2SCN5ASCN9AAURKACDK2 | |
| SCHEMBL28385448 | 0.79 | AURKA (0.59) | KDRAURKACLK4PLK4PDPK1 | |
| SCHEMBL4552673 | 0.77 | APP (0.60) | SCN9AAURKASYKMAPK8AURKB | |
| SCHEMBL28387521 | 0.74 | MEN1 (0.51) | KDRAURKAJAK2CDK1CDK2 | |
| SCHEMBL3594440 | 0.73 | MAOB (0.49) | CLK4SYKCYP1A2CYP3A4TSHR | |
| SCHEMBL255272 | 0.72 | LTA4H (0.67) | SCN9AMAPTTSHRFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HORWELL DAVID CHRISTOPHER (GB) | 2013-03-07 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| CN-101448794-A | Pyrimidine derivatives for the treatment of amyloid-related diseases | SENEXIS LTD (GB) | 2009-06-03 | — | — | CN | disclosed |
| EP-2010502-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | Senexis Limited (GB) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007125351-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063077-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | TYMP, APP, HTT | KCNH2 4622/4885SCN5A 3848/4885SCN9A 4420/4885 |
| US-20130059871-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | TYMP, APP, HTT | KCNH2 4622/4885SCN5A 3848/4885SCN9A 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.